Citation: Jaako P, Debnath S, Olsson K, Modlich U, Rothe M, Schambach A, Flygare J, and Karlsson S. Gene therapy cures the anemia and lethal bone marrow failure in mouse model for RPS19-deficient Diamond-Blackfan anemia. Haematologica. 2014; 99:xxx doi:10.3324/haematol.2014 Enforced expression of ribosomal protein S19 improves the overall proliferative capacity, erythroid colony-forming potential and erythroid differentiation of hematopoietic progenitors from ribosomal protein S19-deficient patients in vitro and in vivo following xenotransplantation. However, studies using animal models are needed to assess the therapeutic efficacy and safety of the viral vectors. In the present study we have validated the therapeutic potential of gene therapy using mouse models for ribosomal protein S19-deficient Diamond-Blackfan anemia. Using lentiviral gene transfer we demonstrate that enforced expression of ribosomal protein S19 cures the anemia and lethal bone marrow failure in recipients transplanted with ribosomal protein S19-deficient cells. Furthermore, gene-corrected ribosomal protein S19-deficient cells showed an increased panhematopoietic contribution over time compared to untransduced cells without signs of vector-mediated toxicity. Our study provides a proof of principle for the development of clinical gene therapy to cure ribosomal protein 19-deficient Diamond-Blackfan anemia.
INTRODUCTION
Diamond-Blackfan anemia (DBA) is a congenital erythroid hypoplasia that present early in infancy. The classic hematologic profile of DBA consists of macrocytic anemia with reticulocytopenia, normal or decreased levels of neutrophils, and variable platelet count 1 . In addition to the hematopoietic symptoms, DBA is characterized by the presence of physical abnormalities and cancer predisposition 2, 3, 4 .
Mutations in genes that encode ribosomal proteins (RPs) have been identified in approximately 60-70 % of DBA patients 5, 6, 7, 8, 9, 10, 11, 12, 13 . Among these genes, RPS19 is the most common DBA gene (25 % of the cases) 5 . All reported patients are heterozygous for the given mutation, and in most cases the mutations are predicted to result in haploinsufficiency of the respective ribosomal protein 14, 15 .
Corticosteroids form the main therapeutic regimen in DBA 4 . However, although approximately 80 % of the patients initially respond to corticosteroids, only half of these patients sustain the therapeutic response, while the remaining patients need chronic transfusion therapy. Twenty percent of the patients undergo spontaneous remission and maintain acceptable hemoglobin level without therapeutic intervention. The only curative treatment for DBA is allogeneic bone marrow (BM) transplantation 16 . Current DBA therapies involve risks for serious side effects, and a high proportion of deaths are treatment-related underscoring the need for development of novel therapies 4 . We have previously demonstrated that enforced expression of RPS19 improves the overall proliferative capacity, erythroid colony-forming potential and erythroid differentiation of hematopoietic progenitors from RPS19-deficient DBA patients 17, 18 . Furthermore, genecorrection of stem cells from RPS19-deficient DBA patients improves their engraftment and erythroid differentiation following transplantation into immunocompromised mice 19 . Despite these encouraging findings, it has not been clear whether gene replacement therapy using ribosomal protein genes can cure the anemia and bone marrow failure in vivo. In the current study we have assessed the therapeutic efficacy and safety of gene therapy using mouse models for RPS19-deficient DBA. We demonstrate that enforced expression of RPS19 fully rescues the anemia and lethal BM failure in these mice, and confers Rps19-deficient cells a repopulation advantage over uncorrected Rps19-deficient cells over time. Collectively our findings demonstrate that development of clinical gene therapy for RPS19-deficient DBA is feasible.
METHODS

Design of lentiviral vector constructs and lentivirus production
Self-inactivating (SIN) lentiviral vectors used in this study were derived from the pRRL.PPT.PGK.GFPpre vector 20 . A codon-optimized human RPS19 cDNA was designed and inserted downstream of the spleen focus-forming virus (SFFV) promoter. Following the RPS19 cDNA, internal ribosomal entry site (IRES), GFP, and improved posttranscriptional regulatory element (Pre*) were inserted to form the pRRL.PPT.SF.RPS19co.iresGFP.pre* vector (hereafter SFFV-RPS19). A similar vector, in which the RPS19 cDNA was replaced with an equally long noncoding spacer sequence, was used as a control (pRRL.PPT.SF.spacer.iresGFP.pre*; hereafter SFFV-GFP). Lentiviral vectors were produced by the Vector Unit at Lund University.
Mice
Generation of the transgenic Rps19 knockdown mice has been reported 
RESULTS
Induction of Rps19 deficiency causes lethal bone marrow failure that is cured by enforced expression of RPS19
As the enforced expression of RPS19 improves the erythroid development in CD34 + cells from RPS19-deficient DBA patients 17, 18, 19 , we asked whether gene therapy could cure the lethal BM failure in our mouse model for RPS19-deficient Figure   6C ). High read clones (>100 reads) were found in both groups at the same level However, the xenograft recipient mice do not develop a hematopoietic phenotype characteristic of DBA and it is therefore essential to ask whether mouse models with severe hematopoietic defects due to Rps19 deficiency can be corrected with gene therapy following RPS19 gene transfer into Rps19-deficient hematopoietic stem cells. Furthermore, studies using mouse models are essential to assess the safety of the therapeutic vectors.
In the current study we decided to utilize the strong and ubiquitously expressed SFFV promoter to provide a proof of principle for the feasibility of gene therapy in the treatment of RPS19-deficient DBA. Furthermore, as codon-optimization of therapeutic genes has been shown to improve gene expression, we designed a codon-optimized human RPS19 cDNA that is not recognized by the Rps19-targeting shRNA. Indeed, the expression of RPS19 driven by the SFFV promoter was approximately 2-fold higher compared to the endogenous Rps19. Consistent with this, we did not observe any hematological abnormalities due to enforced expression of RPS19. Our gene therapy approach to correct Rps19-deficient hematopoiesis required relatively high levels of RPS19 expression and therefore the use of the retroviral SFFV promoter to drive the transgene cassette.
In our experiments and the clonality analysis we did not find signs for overt insertional mutagenesis. However, we cannot fully exclude that the use of a strong internal promoter, such as SFFV, results in a residual risk factor.
Nevertheless, studies assessing the efficacy of clinically relevant promoters like the human phosphoglycerate kinase (PGK) promoter and the elongation factor 1α short (EF1αs) promoter should be performed since these promoters are less likely to cause insertional oncogenesis 29 . Future studies using vectors with these mammalian promoters are needed to ask whether safer vectors can generate sufficient RPS19 expression to correct the pathophysiology of the disease.
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Expression analyses
Total RNA was isolated from cultured cells after two days using the RNAeasy mini kit (Qiagen) and cDNA transcribed with SuperScript III reverse trancriptase (Life Technologies). Rps19 mRNA was quantified by real--time PCR using the SYBR GreenER TM system (5'--GCAGAGGCTCTAAGAGTGTGG--3'; 5'--CCAGGTCTCTCTGTCCCTGA--3') according to manufacturer's instructions (Life Technologies, 11761--500).
LAM--PCR and insertion site analysis
Linear amplification--mediated PCR (LAM--PCR) (Schmidt M et al., Nat Methods.
2007) was performed on 300 ng of whole BM genomic DNA using 5 units of the enzyme Tsp509l, TaqIα and HaeIII. Samples were subject to linear amplification, before they were split in three separate digestion reactions. After restriction enzyme specific linker ligation, the samples were unified again for the nested PCR reactions. Barcoding, sequencing and bioinformatic analysis using custom Perl scripts, HISAP and MAVRIC (http://mavric.erasmusmc.nl/) were performed as described previously (Rittelmeyer and Rothe et al., Hepatology 2013).
Statistical analyses
One--way ANOVA with Tukey's multiple--comparison test was used to determine statistical significance using Prism (version 6, GraphPad Software). 
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